Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 8/20 | 0.55 |
| ▸ | CCNE1 | P24864 | 7/20 | 0.55 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.55 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.55 |
| ▸ | CDK7 | P50613 | 2/20 | 0.55 |
| ▸ | CCNH | P51946 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.47 |
| ▸ | CDK9 | P50750 | 2/20 | 0.47 |
| ▸ | CCNE2 | O96020 | 3/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | CCNT2 | O60583 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.44 |
| ▸ | CDK1 | P06493 | 2/20 | 0.44 |
| ▸ | CTSL | P07711 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL786457 | 0.88 | CDK2 (0.56) | CDK2CCNE1CDK5CDK5R1CDK7 | |
| SCHEMBL15117597 | 0.87 | CDK2 (0.59) | CDK2CCNE1CDK5CDK5R1CDK7 | |
| SCHEMBL15117944 | 0.87 | CDK2 (0.71) | CDK2CCNE1CDK5CDK5R1CDK7 | |
| SCHEMBL15117957 | 0.86 | CDK2 (0.58) | CDK2CCNE1CDK5CDK5R1CDK7 | |
| SCHEMBL15118023 | 0.86 | CDK2 (0.58) | CDK2CCNE1CDK5CDK5R1CDK7 | |
| SCHEMBL786804 | 0.86 | CDK2 (0.58) | CDK2CCNE1CDK5CDK5R1CDK7 | |
| SCHEMBL15117864 | 0.86 | CDK2 (0.58) | CDK2CCNE1CDK5CDK5R1CDK7 | |
| SCHEMBL15117728 | 0.85 | CDK2 (0.57) | CDK2CCNE1CDK5CDK5R1CDK7 | |
| SCHEMBL786323 | 0.83 | CDK2 (0.58) | CDK2CCNE1CDK5CDK5R1CDK7 | |
| SCHEMBL786229 | 0.83 | CCNE1 (0.54) | CDK2CCNE1CDK5CDK5R1CDK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2438068-B1 | SUBSTITUTED 6-(2-HYDROXYBENZYLAMINO)PURINE DERIVATIVES, THEIR USE AS MEDICAMENTS AND COMPOSITIONS CONTAINING THESE DERIVATIVES | Univerzita Palackého v Olomouci (CZ) | 2017-03-01 | — | — | EP | claimed |
| US-8492391-B2 | Substituted 6-(2-hydroxybenzylamino)purine derivatives, their use as medicaments and compositions containing these derivatives | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2013-07-23 | — | — | US | claimed |
| EP-2438068-A1 | SUBSTITUTED 6-(2-HYDROXYBENZYLAMINO)PURINE DERIVATIVES, THEIR USE AS MEDICAMENTS AND COMPOSITIONS CONTAINING THESE DERIVATIVES | Univerzita Palackého v Olomouci (CZ) | 2012-04-11 | — | — | EP | claimed |
| US-20120070512-A1 | Substituted 6-(2-hydroxybenzylamino)purine Derivatives, Their Use as Medicaments and Compositions Containing These Derivatives | BIOPATTERNS, S.R.O (CZ) | 2012-03-22 | — | — | US | claimed |
| WO-2010139289-A1 | SUBSTITUTED 6-(2-HYDROXYBENZYLAMINO)PURINE DERIVATIVES, THEIR USE AS MEDICAMENTS AND COMPOSITIONS CONTAINING THESE DERIVATIVES | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2010-12-09 | — | — | WO | claimed |
| EP-2438068-B1 | SUBSTITUTED 6-(2-HYDROXYBENZYLAMINO)PURINE DERIVATIVES, THEIR USE AS MEDICAMENTS AND COMPOSITIONS CONTAINING THESE DERIVATIVES | Univerzita Palackého v Olomouci (CZ) | 2017-03-01 | — | — | EP | disclosed |
| US-8492391-B2 | Substituted 6-(2-hydroxybenzylamino)purine derivatives, their use as medicaments and compositions containing these derivatives | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2013-07-23 | — | — | US | disclosed |
| EP-2438068-A1 | SUBSTITUTED 6-(2-HYDROXYBENZYLAMINO)PURINE DERIVATIVES, THEIR USE AS MEDICAMENTS AND COMPOSITIONS CONTAINING THESE DERIVATIVES | Univerzita Palackého v Olomouci (CZ) | 2012-04-11 | — | — | EP | disclosed |
| US-20120070512-A1 | Substituted 6-(2-hydroxybenzylamino)purine Derivatives, Their Use as Medicaments and Compositions Containing These Derivatives | BIOPATTERNS, S.R.O (CZ) | 2012-03-22 | — | — | US | disclosed |
| WO-2010139289-A1 | SUBSTITUTED 6-(2-HYDROXYBENZYLAMINO)PURINE DERIVATIVES, THEIR USE AS MEDICAMENTS AND COMPOSITIONS CONTAINING THESE DERIVATIVES | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2010-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120070512-A1 | Substituted 6-(2-hydroxybenzylamino)purine Derivatives, Their Use as Medicaments and Compositions Containing These Derivatives | CDK6, CCNI, CDK2 | CDK2 3/4885CCNE1 80/4885CDK5 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.